

Reference:	FOI.19637.26
Subject:	Gastroenterology
Date of Request:	17 February 2026

Request and response:

How many new patients were treated by the Trust's Gastroenterology Department in the latest 3-month period of November, December and January (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Crohn's disease and Ulcerative colitis? I have provided a table below. Some treatments can only be used for one condition, which I have blocked out.

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st November 2025, they are not classed as a new patient for the purposes of this question.

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients due to the low numbers (less than 5) and have therefore, replaced the figures in the table overleaf with an asterisk (*), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act.

This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

The UHB provides the information requested within the table below, for the period 1 November 2025 to 31 January 2026.

Treatment	Gastroenterology Department total	Crohn's Disease	Ulcerative Colitis
Adalimumab [Humira]	0	0	0
Adalimumab [All Biosimilar]	11	10	*
Etrasimod	*		*
Filgotinib	*		*
Golimumab	0	0	0
Guselkumab	0	0	0
Infliximab [Remicade]	0	0	0
Infliximab [All Biosimilar]	8	6	*
Mirikizumab	0	0	0
Ozanimod	0		0
Risankizumab	*	*	0
Tofacitinib	0		0

Upadacitinib	9	*	8
Ustekinumab [Stelara]	0	0	0
Ustekinumab [All Biosimilar]	*	*	0
Vedolizumab	12	5	7